Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Convulsive status epilepticus (CSE) is a medical emergency that requires prompt treatment. While there is high-quality evidence to support use of benzodiazepines as first-line therapy for CSE, the historical use of phenytoin as the second-line therapy for benzodiazepine-resistant seizures is based on limited evidence.1 Phenytoin has several disadvantages including a long infusion time, drug interactions, a narrow therapeutic index and adverse events such as cardiac arrhythmias, hepatotoxicity, pancytopenia and Stevens-Johnson syndrome. Since the approval of an intravenous formulation of levetiracetam in 2006, it has been considered as an alternative medication for use in benzodiazepine-resistant CSE as it can be administered quickly as an intravenous push, has minimal drug interactions, reliable pharmacokinetics and few serious side effects. Thus, there has been a recent explosion in the number of randomised controlled trials (RCTs) comparing the safety and efficacy of levetiracetam for benzodiazepine-resistant CSE, with 10 RCTs reported since 2018. Similarly, in light of recent data on safety and efficacy of levetiracetam, at least three systematic reviews with meta-analyses are reported so …
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Commissioned; internally peer reviewed.